News | September 03, 2014

Research at Jobst Vascular Institute Examines Safety and Effectiveness of Stents for Veins

September 3, 2014 — Jobst Vascular Institute is conducting pioneering research that looks at using stents to treat blocked veins. For years, stents have been used to treat narrowed or blocked arteries; however none are specifically designed for use in veins. The Cook Medical VIVO clinical research study aims to determine the safety and effectiveness of the Zilver vena venous self-expanding stent in the treatment of vein obstructions. Jobst Vascular Institute is the second center in the country to enroll a patient in the VIVO clinical research study.

“Veins differ greatly from arteries and require a different approach when treating blockages,” said Anthony Comerota, M.D., one of two global principal investigators in the VIVO clinical research study. “While arteries are muscular and under high pressure as they deliver blood throughout the body, veins are low-pressure vessels that return blood to the heart. When obstructed, they require stent characteristics different from those required by an artery.”

Vein obstruction or iliofemoral venous outflow obstruction is a blockage or narrowing of the major veins draining blood from the leg. It causes leg pain, throbbing, swelling and skin discoloration in the legs. It may also be associated with deep vein thrombosis, a blood clot in the leg. Patients are currently treated only with compression stockings or by elevating the leg. Some patients may be taking blood thinners.

“This is an important trial, which may expand the options for treating diseased veins,” said Comerota.

The Zilver vena venous self-expanding stent is an investigational device that is not approved for sale in the United States.

For more information:,

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init